Pennsylvania Patent of the Month – August 2024
Rhoshan Pharmaceuticals, Inc. has pioneered a novel lyophilized aspirin composition that addresses long-standing challenges in the medical field. Traditionally, aspirin has been used effectively for pain relief and anti-inflammatory purposes, yet its injectable forms have faced significant stability issues. Rhoshan has combined crystalline aspirin in its free acid form with a carefully selected bulking agent and surfactant, creating a formulation that remains stable for at least two years at room temperature.
What sets this composition apart is its unique reflection X-ray powder diffraction pattern, specifically characterized by distinct peaks, enabling precise identification and quality control. This specificity not only ensures consistent therapeutic efficacy but also reduces degradation, which has plagued previous formulations. The melting point of the crystalline aspirin—determined by differential scanning calorimetry—further enhances the formulation’s reliability, making it suitable for immediate therapeutic use.
Rhoshan’s composition also integrates a liquid solution that enhances the stability of aspirin before lyophilization. By using a cosolvent mix of t-butyl alcohol and water, this formulation achieves solubility levels exceeding 100 mg/mL at optimal pH levels, which is crucial for effective intravenous delivery. This means rapid onset of action—critical in acute medical scenarios like heart attacks or strokes—can be achieved much faster than with oral administration.
The innovative lyophilized aspirin not only meets a critical medical need but also opens new avenues for treatment methodologies. By offering an injectable form of aspirin with immediate effects, Rhoshan Pharmaceuticals is poised to redefine pain management and anti-thrombotic therapies, ensuring patient safety and effectiveness in emergency care. This advancement highlights the ongoing importance of R&D in creating next-generation pharmaceuticals.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
